A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(17 sites)

United States

Providence Medical Foundation, Fullerton, California

University of California Irvine, Irvine, California

Children's Hospital Los Angeles Division Of Rheumatology, Los Angeles, California

University of California San Francisco, San Francisco, California

University of Minnesota Medical School, Minneapolis, Minnesota